Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levetiracetam in Tardive Dyskinesia
NCT00291213Phase 3
Key facts
- Status
- Completed
- Primary completion
- Apr 2006
- Countries
- 1
- Sponsor
- Yale University
- Modality
- Small Molecules
- Drugs
- levetiracetam
- Conditions
- tardive dyskinesia (TD)
01
Overview
Phase 3, randomised, double-blind trial of levetiracetam in tardive dyskinesia (TD) (2 arms), sponsored by Yale University. Primary endpoint: Abnormal Involuntary Movement Scale at 12 weeks. Status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Levetiracetram Administration
Experimental arm receiving levetiracetam
Placebo
Comparator arm receiving placebo
03
Who it enrols
Patients must meet Glazer Morgenstern criteria for Tardive Dyskinesia. There are no exclusion criteria.
04
Endpoints
Primary
Abnormal Involuntary Movement Scale
Beyond the preview
Go deeper on NCT00291213.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00291213.